Understanding an abnormal Cologuard result, also known as a positive Cologuard or abnormal FIT-DNA test? This guide provides information on clinical documentation, medical coding, and next steps for healthcare professionals dealing with positive Cologuard screenings. Learn about the significance of an abnormal Cologuard and its implications for patient care.
A positive Cologuard stool test suggests the presence of colorectal cancer or advanced precancerous polyps.
Often asymptomatic. May include changes in bowel habits, blood in stool, abdominal pain, or unexplained weight loss.
Primary care, gastroenterology clinics, colonoscopy screening programs.
Complete code families applicable to R19.5
| Description | When to use |
|---|---|
| Cologuard result indicates possible colon cancer or polyps. | Use for positive Cologuard results requiring follow-up colonoscopy. Consider 'Abnormal FIT-DNA Test'. |
| Fecal immunochemical test detects blood in stool, possible colon issues. | Use for positive FIT results. Order if Cologuard is unavailable or patient prefers. Screen for colorectal cancer. |
| Visual exam of colon detects polyps or cancer. | Use for documenting findings from colonoscopy procedure performed due to abnormal Cologuard or FIT. |
Coding 'Abnormal Cologuard' lacks specificity. Document and code the specific finding (e.g., positive for blood, DNA markers) for accurate reimbursement and quality reporting. Relevant to medical coding, CDI, healthcare compliance.
Abnormal Cologuard necessitates follow-up colonoscopy. Lack of documentation of recommended colonoscopy impacts quality measures and may trigger medical necessity denials. Important for medical coding, CDI, and healthcare compliance.
Using unspecified codes for positive Cologuard or FIT-DNA tests leads to inaccurate data reporting and potential compliance issues. Proper coding is crucial for medical coding, CDI specialists, and healthcare compliance.
Review patient symptoms and risk factors (age, family history).
Confirm proper Cologuard collection and processing per guidelines.
Evaluate for interfering factors (bleeding, medications).
Document Cologuard result, CPT code 81528, and rationale for next steps.
Recommend diagnostic colonoscopy per guidelines (CPT 45380).
Patient presents for follow-up regarding an abnormal Cologuard result. The patient completed the FIT-DNA stool test (Cologuard) as a colorectal cancer screening alternative to colonoscopy. The positive Cologuard result indicates the presence of altered DNA andor hemoglobin in the stool sample, raising concern for colorectal neoplasia. The patient reports no significant gastrointestinal symptoms such as abdominal pain, rectal bleeding, or changes in bowel habits. Past medical history is significant for (list relevant conditions). Family history is negativepositive for colorectal cancer (specify). A colonoscopy is recommended to evaluate for colorectal polyps or cancer and is scheduled for (date). Pre-procedure instructions, including bowel preparation guidelines, were reviewed with the patient. The importance of colonoscopy for definitive diagnosis and potential therapeutic intervention was emphasized. Risks and benefits of the procedure were discussed, and informed consent was obtained. ICD-10 code R19.5 (Other fecal abnormalities) is considered for this abnormal screening result, pending colonoscopy findings. CPT code 81528 will be billed for the Cologuard test itself. This plan is consistent with current colorectal cancer screening guidelines, including those from the US Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS). Further evaluation and management will be determined based on the colonoscopy findings.
While an abnormal Cologuard (positive Cologuard or abnormal FIT-DNA test) can indicate colorectal cancer (CRC), it's crucial to remember that the majority of positive results in asymptomatic patients are due to benign conditions like polyps, hemorrhoids, diverticulitis, or even medications like NSAIDs. The next step after a positive Cologuard is always a colonoscopy to visualize the colon and obtain tissue biopsies if necessary. This allows for definitive diagnosis and potential removal of precancerous polyps. Pre-colonoscopy assessment should include a thorough review of the patient's medical history, medications, and bleeding risk factors. Explore how risk stratification can help guide your management decisions. Consider implementing standardized pre-colonoscopy protocols to ensure consistent and comprehensive patient care.
Explaining a positive Cologuard result requires sensitivity and clarity. Emphasize that a positive result doesn't automatically equate to colorectal cancer. Explain that the test detects altered DNA and blood in the stool, which can be caused by various factors, including precancerous polyps, benign growths, and non-cancerous conditions. Reassure the patient that the next step, a diagnostic colonoscopy, is essential to determine the exact cause of the positive result and, if necessary, remove any polyps. Openly discuss the colonoscopy procedure, addressing any anxieties they might have about the preparation, the procedure itself, or potential findings. Provide educational resources about colonoscopy and emphasize its role in both diagnosis and prevention of CRC. Learn more about effective communication strategies for delivering sensitive medical information to anxious patients.
Post-colonoscopy surveillance intervals after an abnormal Cologuard are determined by the findings of the colonoscopy. If only hyperplastic polyps are found, repeat Cologuard testing or colonoscopy may be recommended in 10 years, assuming the patient remains average-risk. However, if adenomatous polyps or sessile serrated adenomas are detected, surveillance intervals are generally shorter, typically ranging from 3 to 5 years or even sooner depending on the size, number, and histology of the polyps. Clearly communicate the rationale behind these surveillance intervals to the patient and emphasize the importance of adherence. Consider implementing patient reminder systems and educational programs to optimize surveillance compliance and improve long-term outcomes. Explore how personalized risk assessment tools can refine surveillance strategies for individual patients.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.